Clinical Trials Directory

Trials / Completed

CompletedNCT01014871

Comparison of Two Botulinum Toxins Type A on Forehead Wrinkles

Intra-individual Comparison of the Efficacy of Two Botulinum Toxins Type A on Moderate to Severe Forehead Wrinkles After One Injection

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
30 (actual)
Sponsor
Galderma R&D · Industry
Sex
Female
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Single-centre, controlled, randomized, evaluator-blinded, bilateral (split-face) comparison study in subjects with moderate to severe forehead wrinkles. One botulinum toxin type A will be injected in one side of the forehead and the other one will be injected in the other side of the forehead at baseline. Allocation of each BoNT-A to each side of the forehead will be randomized.

Detailed description

There are two formulations of BoNT-A available: Botox®/Vistabel®, Allergan and Dysport®/Azzalure®, Ipsen - Galderma. These formulations behave distinctly in different ways electrophysiologically and clinically and results obtained with one formulation cannot be extrapolated to the other. There are only few clinical research directly comparing the two formulations in the treatment of forehead lines.

Conditions

Interventions

TypeNameDescription
DRUGBotulinum Toxin Type A - AzzalureOne botulinum toxin type A will be injected in one side of the forehead and the other one will be injected in the other side of the forehead at Baseline. Allocation of each BoNT-A to each side of the forehead will be randomized.
DRUGBotulinum Toxin Type A - VistabelOne botulinum toxin type A will be injected in one side of the forehead and the other one will be injected in the other side of the forehead at Baseline. Allocation of each BoNT-A to each side of the forehead will be randomized.

Timeline

Start date
2009-07-01
Primary completion
2010-04-01
Completion
2010-05-01
First posted
2009-11-17
Last updated
2021-02-18
Results posted
2012-04-05

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT01014871. Inclusion in this directory is not an endorsement.